Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

The Lancet

Volumn 372, Issue 9634, 2008, Pages 207-215

  Doody, Rachelle S ^a   Gavrilova, Svetlana I ^b   Sano, Mary ^c   Thomas, Ronald G ^d   Aisen, Paul S ^e   Bachurin, Sergey O ^f   Seely, Lynn ^g   Hung, David ^g  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f INSTITUTE OF PHYSIOLOGICALLY ACTIVE COMPOUNDS   (Russian Federation)

^g Medivation Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ANXIOLYTIC AGENT; DIMEBON; HYPNOTIC AGENT; PHENOBARBITAL; PLACEBO; PSYCHOTROPIC AGENT; SEDATIVE AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ANGINA PECTORIS; ARTICLE; ASTHENIA; BEHAVIOR; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; DYSPNEA; FEMALE; HEART ATRIUM FLUTTER; HUMAN; HYPERHIDROSIS; HYPERKALEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MOTOR DYSFUNCTION; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; PATIENT COMPLIANCE; POLYURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RUSSIAN FEDERATION; SIDE EFFECT; TREATMENT OUTCOME; XEROSTOMIA;

EID: 47149108940     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61074-0     Document Type: Article

References (27)

1. Cummings J. Alzheimer's disease. N Engl J Med 351 (2004) 56-67
2. Ferri C., Prince M., Brayne C., et al., for Alzheimer's Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet 366 (2005) 2112-2117
3. Hebert L., Scherr P., Bienias J., Bennett D., and Evans D. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60 (2003) 1119-1122
4. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 1 (2006) CD005593.
5. Bachurin S., Bukatina E., Lermontova N., et al. Antihistamine agent dimebon as a novel neuroprotector and a cognition enhancer. Ann NY Acad Sci 939 (2001) 425-435
6. 2+ channels. Bull Exp Biol Med 5 (2001) 1079-1083
7. Grigor'ev V., Dranyi O., and Bachurin S. Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull Exp Biol Med 136 (2003) 474-477
8. Bachurin S., Shevtsova E., Kireeva E., Oxenkrug G., and Sablin S. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann NY Acad Sci 993 (2003) 334-344
9. Diagnostic and statistical manual of mental disorders. 4th edn. (1994), American Psychiatric Association, Washington DC (DSM-IV).
10. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group, under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
11. Folstein M., Folstein S., and McHugh P. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
12. Cockrell J., and Folstein M. Mini-mental state examination (MMSE). Psychopharm Bull 24 (1988) 689-692
13. Rosen W., Terry R., Fuld P., Katzman R., and Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 7 (1980) 486-488
14. Rosen W., Mohs R., and Davis K. A new rating scale for Alzheimer's disease. Am J Psychiatry 141 (1984) 1356-1364
15. Cummings J., Mega M., Gray K., Rosenberg-Thompson S., Carusi D., and Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44 (1994) 2308-2314
16. Galasko D., Bennett D., Sano M., et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord 11 suppl 2 (1997) S33-S39
17. Reisberg B., Schneider L., Doody R., et al. Clinical global measures of dementia: position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 11 suppl 3 (1997) 8-18
18. Schneider L., Olin J., Doody R., et al. Validity and reliability of the Alzheimer's disease cooperative study-clinical global impression of change. Alzheimer Dis Assoc Disord 11 suppl 2 (1997) 22-32
19. Raskind M., Peskind E., Wessel T., and Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 54 (2000) 2261-2268
20. Rogers S., Farlow M., Doody R., Mohs R., and Friedhoff L. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 50 (1998) 136-145
21. Wilcock G., Lilienfield S., and Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ 321 (2000) 1445-1449
22. Farlow M., Anand R., Messina J., Hartman R., and Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 44 (2000) 236-241
23. Estelle F., Simons R., and Simons K. The pharmacology and use of H1-receptor-antagonist drugs. N Engl J Med 330 (1994) 1663-1670
24. McShane R., Areosa S.A., and Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2 (2006) CD003154.
25. Karlawish J., and Whitehouse P. Is the placebo obsolete in a world after donepezil and vitamin E?. Arch Neurol 55 (1998) 1420-1424
26. Winblad B., Engedal K., Soininen H., et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57 (2001) 489-495
27. Mohs R., Doody R., Morris J., et al. A 1-year placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57 (2001) 481-488